Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGCG | Q16739 | 8/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29839299 | 1.00 | UGCG (0.67) | UGCGMAPTKDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL22729643 | 0.89 | UGCG (0.51) | UGCGMAPTKDM4ESCN9A | |
| SCHEMBL29839326 | 0.89 | UGCG (0.51) | UGCGMAPTKDM4ESCN9A | |
| SCHEMBL29839303 | 0.86 | UGCG (0.48) | UGCGMAPTSCN9A | |
| SCHEMBL29839298 | 0.86 | UGCG (0.48) | UGCGMAPTSCN9ANR3C1 | |
| SCHEMBL22729530 | 0.86 | UGCG (0.48) | UGCGMAPTSCN9A | |
| SCHEMBL22729804 | 0.86 | UGCG (0.48) | UGCGMAPTSCN9ANR3C1 | |
| SCHEMBL22729611 | 0.85 | UGCG (0.49) | UGCGMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL29839394 | 0.85 | UGCG (0.49) | UGCGMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL22729450 | 0.85 | UGCG (0.47) | UGCGMAPTKDM4ESMN1; SMN2SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459325-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-10-04 | — | — | US | claimed |
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | US | claimed |
| EP-3747885-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-12-09 | — | — | EP | claimed |
| US-11459325-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-10-04 | — | — | US | disclosed |
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | US | disclosed |
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | US | disclosed |
| EP-3747885-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-12-09 | — | — | EP | disclosed |
| EP-3747885-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | UGCG 8/4885MAPT 356/4885KDM4E 1315/4885 |
| US-11459325-B2 | Heterocyclic compound | GBA1, GBA2, GALC | UGCG 8/4885MAPT 364/4885KDM4E 1270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.